Niessner, H.; Hüsch, A.; Kosnopfel, C.; Meinhardt, M.; Westphal, D.; Meier, F.; Schilling, B.; Sinnberg, T.
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma. Cancers 2023, 15, 5521.
https://doi.org/10.3390/cancers15235521
AMA Style
Niessner H, Hüsch A, Kosnopfel C, Meinhardt M, Westphal D, Meier F, Schilling B, Sinnberg T.
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma. Cancers. 2023; 15(23):5521.
https://doi.org/10.3390/cancers15235521
Chicago/Turabian Style
Niessner, Heike, Anna Hüsch, Corinna Kosnopfel, Matthias Meinhardt, Dana Westphal, Friedegund Meier, Bastian Schilling, and Tobias Sinnberg.
2023. "Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma" Cancers 15, no. 23: 5521.
https://doi.org/10.3390/cancers15235521
APA Style
Niessner, H., Hüsch, A., Kosnopfel, C., Meinhardt, M., Westphal, D., Meier, F., Schilling, B., & Sinnberg, T.
(2023). Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma. Cancers, 15(23), 5521.
https://doi.org/10.3390/cancers15235521